Sun Pharmaceutical Industries said it will buy Organon & Co. for $14 per share in cash, valuing the deal at an enterprise value of $11.75 billion. The transaction is a major acquisition in healthcare and should be supportive for Sun Pharma's strategic scale and portfolio expansion. The announcement is likely to move both companies' shares and is material for sector M&A activity.
Sun Pharmaceutical Industries said it will buy Organon & Co. for $14 per share in cash, valuing the deal at an enterprise value of $11.75 billion. The transaction is a major acquisition in healthcare and should be supportive for Sun Pharma's strategic scale and portfolio expansion. The announcement is likely to move both companies' shares and is material for sector M&A activity.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
